Department of Emergency, Jiangxi Provincial People's Hospital, 92 AiGuo St., Nanchang, 330006, Jiangxi, China.
Medical Department, Nanchang University, Nanchang, Jiangxi, China.
Scand J Trauma Resusc Emerg Med. 2022 Apr 18;30(1):28. doi: 10.1186/s13049-022-01015-3.
Intravenous fluids are used commonly for almost all intensive care unit (ICU) patients, especially for patients in need of resuscitation. The selection and use of resuscitation fluids may affect the outcomes of patients; however, the optimal resuscitative fluid remains controversial.
We systematically searched PubMed, Embase, and CENTRAL. Studies comparing balanced crystalloids and normal saline in ICU patients were selected. We used the Cochrane Collaboration tool to assess the risk of bias in studies. The primary outcome was mortality at the longest follow-up. Secondary outcomes included the incidence of acute kidney injury (AKI) and new renal replacement therapy (RRT).
A total of 35,456 patients from eight studies were included. There was no significant difference between balanced crystalloid solutions and saline in mortality (risk ratio [RR]: 0.96; 95% confidence interval [CI]:0.92-1.01). The subgroup analysis with traumatic brain injury (TBI) showed lower mortality in patients receiving normal saline (RR:1.25; 95% CI 1.02-1.54). However, in patients with non-TBI, balanced crystalloid solutions achieved lower mortality than normal saline (RR: 0.94; 95% CI 0.90-0.99). There was no significant difference in moderate to severe AKI (RR: 0.96; 95% CI 0.90-1.01) or new RRT (RR: 0.94; 95% CI 0.84-1.04).
Compared with normal saline, balanced crystalloids may not improve the outcomes of mortality, the incidence of AKI, and the use of RRT for critically ill patients. However, balanced crystalloids reduce the risk of death in patients with non-TBI but increase the risk of death in those with TBI. Large-scale rigorous randomized trials with better designs are needed, especially for specific patient populations.
静脉输液通常用于几乎所有重症监护病房(ICU)患者,尤其是需要复苏的患者。复苏液的选择和使用可能会影响患者的预后,但最佳复苏液仍存在争议。
我们系统地检索了 PubMed、Embase 和 CENTRAL。选择了比较平衡晶体液和生理盐水在 ICU 患者中的研究。我们使用 Cochrane 协作工具评估研究的偏倚风险。主要结局是最长随访时的死亡率。次要结局包括急性肾损伤(AKI)和新的肾脏替代治疗(RRT)的发生率。
共有来自八项研究的 35456 名患者纳入研究。平衡晶体液与生理盐水在死亡率方面无显著差异(风险比 [RR]:0.96;95%置信区间 [CI]:0.92-1.01)。亚组分析显示,接受生理盐水的创伤性脑损伤(TBI)患者死亡率较低(RR:1.25;95% CI 1.02-1.54)。然而,在非 TBI 患者中,平衡晶体液的死亡率低于生理盐水(RR:0.94;95% CI 0.90-0.99)。中重度 AKI(RR:0.96;95% CI 0.90-1.01)或新的 RRT(RR:0.94;95% CI 0.84-1.04)发生率无显著差异。
与生理盐水相比,平衡晶体液可能不会改善死亡率、AKI 发生率和 RRT 的使用,对危重症患者的预后无影响。但平衡晶体液降低了非 TBI 患者的死亡风险,增加了 TBI 患者的死亡风险。需要开展设计更好的大规模严格随机试验,特别是针对特定患者人群。